DiaMedica Therapeutics Inc. (DMAC) Financial Statements
Free cash flow over the same period: -$31.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DMACDiaMedica Therapeutics Inc.Follow DMAC — free
—
Price chart with a free account
- Market cap
- 470.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | 4.5 | 7.9 | 8.2 | 8.8 | 7.8 | 13.1 | 19.1 | 24.6 | 29.3 | |
| Operating income | -6.8 | -11.6 | -12.7 | -13.6 | -14.0 | -21.3 | -26.7 | -34.4 | -39.2 | |
| Pre-tax income | -5.7 | -10.6 | -12.3 | -13.6 | -13.6 | -19.3 | -24.4 | -32.7 | -37.5 | |
| Income tax | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net income | -5.7 | -10.6 | -12.3 | -13.6 | -13.7 | -19.4 | -24.4 | -32.8 | -37.5 | |
| Diluted EPS ($) | -0.74 | -0.89 | -0.78 | -0.65 | — | — | — | — | — |
USD millions · SEC XBRL
DiaMedica Therapeutics Inc. — questions
- What is DiaMedica Therapeutics Inc.'s net income?
- -$37.5M over the twelve months to 2026-06-30.
- What is DiaMedica Therapeutics Inc.'s free cash flow?
- -$31.5M over the twelve months to 2026-06-30.
Every figure on this page comes from DiaMedica Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.